Is Foghorn TherapeuticsInc Stock a Good Investment?
Foghorn TherapeuticsInc Investment Advice | FHTX |
- Examine Foghorn TherapeuticsInc's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Foghorn TherapeuticsInc's leadership team and their track record. Good management can help Foghorn TherapeuticsInc navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Foghorn TherapeuticsInc's business and its evolving consumer preferences.
- Compare Foghorn TherapeuticsInc's performance and market position to its competitors. Analyze how Foghorn TherapeuticsInc is positioned in terms of product offerings, innovation, and market share.
- Check if Foghorn TherapeuticsInc pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Foghorn TherapeuticsInc's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Foghorn TherapeuticsInc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Foghorn TherapeuticsInc is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Foghorn TherapeuticsInc Stock
Researching Foghorn TherapeuticsInc's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.2. Foghorn TherapeuticsInc had not issued any dividends in recent years.
To determine if Foghorn TherapeuticsInc is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Foghorn TherapeuticsInc's research are outlined below:
| Foghorn TherapeuticsInc generated a negative expected return over the last 90 days | |
| Foghorn TherapeuticsInc has high historical volatility and very poor performance | |
| Foghorn TherapeuticsInc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 34.16 M. Net Loss for the year was (98.43 M) with loss before overhead, payroll, taxes, and interest of (86.39 M). | |
| Foghorn TherapeuticsInc currently holds about 373.5 M in cash with (118.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 19.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: Flagship Pioneering funds acquire over 20 million in Foghorn Therapeutics warrants |
Foghorn TherapeuticsInc uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Foghorn TherapeuticsInc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Foghorn TherapeuticsInc's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Foghorn TherapeuticsInc's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Foghorn TherapeuticsInc's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-03-09 | 2022-12-31 | -0.62 | -0.69 | -0.07 | 11 | ||
2022-08-09 | 2022-06-30 | -0.59 | -0.66 | -0.07 | 11 | ||
2022-05-09 | 2022-03-31 | -0.52 | -0.65 | -0.13 | 25 | ||
2024-03-07 | 2023-12-31 | -0.76 | -0.57 | 0.19 | 25 | ||
2022-03-10 | 2021-12-31 | -0.49 | -0.74 | -0.25 | 51 | ||
2023-11-02 | 2023-09-30 | -0.75 | -0.34 | 0.41 | 54 | ||
2020-12-04 | 2020-09-30 | -1.72 | -3.12 | -1.4 | 81 | ||
2021-03-18 | 2020-12-31 | -0.45 | -1.86 | -1.41 | 313 |
Know Foghorn TherapeuticsInc's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Foghorn TherapeuticsInc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Foghorn TherapeuticsInc backward and forwards among themselves. Foghorn TherapeuticsInc's institutional investor refers to the entity that pools money to purchase Foghorn TherapeuticsInc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Birchview Capital, Lp | 2023-12-31 | 320.9 K | Jacobs Levy Equity Management, Inc. | 2024-03-31 | 216.3 K | Northern Trust Corp | 2023-12-31 | 199.3 K | Sio Capital Management, Llc | 2023-12-31 | 121.7 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 105.1 K | Panagora Asset Management Inc | 2023-12-31 | 97 K | Millennium Management Llc | 2024-03-31 | 62 K | Bank Of New York Mellon Corp | 2023-12-31 | 57.2 K | Charles Schwab Investment Management Inc | 2024-03-31 | 55.4 K | Flagship Ventures Management, Inc. | 2024-03-31 | 12.7 M | Fmr Inc | 2023-12-31 | 2.8 M |
Foghorn TherapeuticsInc's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 312.05 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Foghorn TherapeuticsInc's market, we take the total number of its shares issued and multiply it by Foghorn TherapeuticsInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Foghorn TherapeuticsInc's profitablity analysis
Foghorn TherapeuticsInc's profitability indicators refer to fundamental financial ratios that showcase Foghorn TherapeuticsInc's ability to generate income relative to its revenue or operating costs. If, let's say, Foghorn TherapeuticsInc is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Foghorn TherapeuticsInc's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Foghorn TherapeuticsInc's profitability requires more research than a typical breakdown of Foghorn TherapeuticsInc's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.47) | (0.50) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | 1.28 | 1.34 |
Determining Foghorn TherapeuticsInc's profitability involves analyzing its financial statements and using various financial metrics to determine if Foghorn TherapeuticsInc is a good buy. For example, gross profit margin measures Foghorn TherapeuticsInc's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Foghorn TherapeuticsInc's profitability and make more informed investment decisions.
The data published in Foghorn TherapeuticsInc's official financial statements usually reflect Foghorn TherapeuticsInc's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Foghorn TherapeuticsInc. For example, before you start analyzing numbers published by Foghorn accountants, it's critical to develop an understanding of what Foghorn TherapeuticsInc's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Foghorn TherapeuticsInc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Foghorn TherapeuticsInc's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Foghorn TherapeuticsInc's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Foghorn TherapeuticsInc. Please utilize our Beneish M Score to check the likelihood of Foghorn TherapeuticsInc's management manipulating its earnings.
Evaluate Foghorn TherapeuticsInc's management efficiency
Foghorn TherapeuticsInc has return on total asset (ROA) of (0.2046) % which means that it has lost $0.2046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7038) %, meaning that it created substantial loss on money invested by shareholders. Foghorn TherapeuticsInc's management efficiency ratios could be used to measure how well Foghorn TherapeuticsInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.34 in 2024, whereas Return On Tangible Assets are likely to drop (0.36) in 2024. At this time, Foghorn TherapeuticsInc's Debt To Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 0.84 in 2024, whereas Total Assets are likely to drop slightly above 280.8 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.84) | (1.75) | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (1.84) | (1.75) | |
| Enterprise Value Over EBITDA | (2.37) | (2.49) | |
| Price Book Value Ratio | (3.51) | (3.33) | |
| Enterprise Value Multiple | (2.37) | (2.49) | |
| Price Fair Value | (3.51) | (3.33) | |
| Enterprise Value | 235.5 M | 223.7 M |
The analysis of Foghorn TherapeuticsInc's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Foghorn TherapeuticsInc's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Foghorn Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 3.151 |
Basic technical analysis of Foghorn Stock
As of the 26th of May, Foghorn TherapeuticsInc shows the Mean Deviation of 4.61, coefficient of variation of 9074.3, and Downside Deviation of 5.9. Foghorn TherapeuticsInc technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Foghorn TherapeuticsInc, which can be compared to its peers. Please confirm Foghorn TherapeuticsInc mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Foghorn TherapeuticsInc is priced favorably, providing market reflects its regular price of 5.64 per share. Given that Foghorn TherapeuticsInc has jensen alpha of (0.01), we urge you to verify Foghorn TherapeuticsInc's prevailing market performance to make sure the company can sustain itself at a future point.Foghorn TherapeuticsInc's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Foghorn TherapeuticsInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Foghorn TherapeuticsInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Foghorn TherapeuticsInc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Foghorn TherapeuticsInc's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Foghorn TherapeuticsInc's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0155 | |||
| Market Risk Adjusted Performance | 0.0438 | |||
| Mean Deviation | 4.61 | |||
| Semi Deviation | 5.61 | |||
| Downside Deviation | 5.9 | |||
| Coefficient Of Variation | 9074.3 | |||
| Standard Deviation | 6.2 | |||
| Variance | 38.48 | |||
| Information Ratio | 0.0033 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.35) | |||
| Sortino Ratio | 0.0034 | |||
| Treynor Ratio | 0.0338 | |||
| Maximum Drawdown | 40.57 | |||
| Value At Risk | (7.25) | |||
| Potential Upside | 8.89 | |||
| Downside Variance | 34.75 | |||
| Semi Variance | 31.52 | |||
| Expected Short fall | (4.82) | |||
| Skewness | 0.8764 | |||
| Kurtosis | 3.85 |
| Risk Adjusted Performance | 0.0155 | |||
| Market Risk Adjusted Performance | 0.0438 | |||
| Mean Deviation | 4.61 | |||
| Semi Deviation | 5.61 | |||
| Downside Deviation | 5.9 | |||
| Coefficient Of Variation | 9074.3 | |||
| Standard Deviation | 6.2 | |||
| Variance | 38.48 | |||
| Information Ratio | 0.0033 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.35) | |||
| Sortino Ratio | 0.0034 | |||
| Treynor Ratio | 0.0338 | |||
| Maximum Drawdown | 40.57 | |||
| Value At Risk | (7.25) | |||
| Potential Upside | 8.89 | |||
| Downside Variance | 34.75 | |||
| Semi Variance | 31.52 | |||
| Expected Short fall | (4.82) | |||
| Skewness | 0.8764 | |||
| Kurtosis | 3.85 |
Consider Foghorn TherapeuticsInc's intraday indicators
Foghorn TherapeuticsInc intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Foghorn TherapeuticsInc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Foghorn TherapeuticsInc Corporate Filings
F3 | 24th of May 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 23rd of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 3rd of May 2024 Other Reports | ViewVerify | |
F4 | 12th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Foghorn Stock media impact
Far too much social signal, news, headlines, and media speculation about Foghorn TherapeuticsInc that are available to investors today. That information is available publicly through Foghorn media outlets and privately through word of mouth or via Foghorn internal channels. However, regardless of the origin, that massive amount of Foghorn data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Foghorn TherapeuticsInc news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Foghorn TherapeuticsInc relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Foghorn TherapeuticsInc's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Foghorn TherapeuticsInc alpha.
Foghorn TherapeuticsInc Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Foghorn TherapeuticsInc can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Foghorn TherapeuticsInc without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Foghorn TherapeuticsInc Corporate Management
Elected by the shareholders, the Foghorn TherapeuticsInc's board of directors comprises two types of representatives: Foghorn TherapeuticsInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Foghorn. The board's role is to monitor Foghorn TherapeuticsInc's management team and ensure that shareholders' interests are well served. Foghorn TherapeuticsInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Foghorn TherapeuticsInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karin Hellsvik | Corporate VP | Profile | |
| Saurabh Sewak | Vice Development | Profile | |
| Allan MD | Chief Officer | Profile | |
| Alfonso MD | Chief Officer | Profile | |
| Gerald Md | Founder Board | Profile |
How to buy Foghorn Stock?
To provide specific investment advice or recommendations on Foghorn TherapeuticsInc stock, we recommend investors consider the following general factors when evaluating Foghorn TherapeuticsInc. This will help you to make an informed decision on whether to include Foghorn TherapeuticsInc in one of your diversified portfolios:- Examine Foghorn TherapeuticsInc's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Foghorn TherapeuticsInc's leadership team and their track record. Good management can help Foghorn TherapeuticsInc navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Foghorn TherapeuticsInc's business and its evolving consumer preferences.
- Compare Foghorn TherapeuticsInc's performance and market position to its competitors. Analyze how Foghorn TherapeuticsInc is positioned in terms of product offerings, innovation, and market share.
- Check if Foghorn TherapeuticsInc pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Foghorn TherapeuticsInc's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Foghorn TherapeuticsInc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Foghorn TherapeuticsInc is a good investment.
Already Invested in Foghorn TherapeuticsInc?
The danger of trading Foghorn TherapeuticsInc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Foghorn TherapeuticsInc is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Foghorn TherapeuticsInc. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Foghorn TherapeuticsInc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Foghorn TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Foghorn TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Foghorn Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Foghorn Therapeuticsinc Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn TherapeuticsInc guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Foghorn Stock analysis
When running Foghorn TherapeuticsInc's price analysis, check to measure Foghorn TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn TherapeuticsInc is operating at the current time. Most of Foghorn TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Foghorn TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn TherapeuticsInc's price. Additionally, you may evaluate how the addition of Foghorn TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Foghorn TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Foghorn TherapeuticsInc. If investors know Foghorn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Foghorn TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.20) | Revenue Per Share 0.805 | Quarterly Revenue Growth (0.05) | Return On Assets (0.20) | Return On Equity (4.70) |
The market value of Foghorn TherapeuticsInc is measured differently than its book value, which is the value of Foghorn that is recorded on the company's balance sheet. Investors also form their own opinion of Foghorn TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Foghorn TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Foghorn TherapeuticsInc's market value can be influenced by many factors that don't directly affect Foghorn TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Foghorn TherapeuticsInc's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Foghorn TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Foghorn TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.